SG11201807402PA - Compositions - Google Patents

Compositions

Info

Publication number
SG11201807402PA
SG11201807402PA SG11201807402PA SG11201807402PA SG11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA
Authority
SG
Singapore
Prior art keywords
cambridge
vhsquared
copley
cambridgeshire
court
Prior art date
Application number
SG11201807402PA
Other languages
English (en)
Inventor
Scott Crowe
Mike West
Kevin Roberts
Tim Carlton
Luana Maggiore
Marion Cubitt
Gary Whale
John Wahlich
Mike Frodsham
Original Assignee
Vhsquared Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vhsquared Ltd filed Critical Vhsquared Ltd
Publication of SG11201807402PA publication Critical patent/SG11201807402PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SG11201807402PA 2016-03-31 2017-03-31 Compositions SG11201807402PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163178 2016-03-31
PCT/EP2017/057775 WO2017167997A1 (en) 2016-03-31 2017-03-31 Compositions

Publications (1)

Publication Number Publication Date
SG11201807402PA true SG11201807402PA (en) 2018-09-27

Family

ID=55646428

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807402PA SG11201807402PA (en) 2016-03-31 2017-03-31 Compositions

Country Status (10)

Country Link
US (2) US10772839B2 (enExample)
EP (1) EP3435982A1 (enExample)
JP (2) JP7224917B2 (enExample)
KR (1) KR102376369B1 (enExample)
CN (2) CN117243904A (enExample)
AU (2) AU2017240190A1 (enExample)
CA (2) CA3019482A1 (enExample)
IL (1) IL261792B (enExample)
SG (1) SG11201807402PA (enExample)
WO (2) WO2017167997A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
EP3277719B1 (en) * 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions
WO2018060453A1 (en) * 2016-09-30 2018-04-05 Vhsquared Limited Compositions
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CA3054632A1 (en) * 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN115605485A (zh) * 2020-05-18 2023-01-13 深圳市塔吉瑞生物医药有限公司（Cn） 大环化合物的固体形式及其制备和用途
CN113768051B (zh) * 2020-06-09 2024-03-19 中粮营养健康研究院有限公司 饲料添加剂及其制备方法和其在饲料中的应用以及替抗饲料
GB202017863D0 (en) * 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
MX2023012437A (es) * 2021-04-22 2023-11-07 Civi Biopharma Inc Administracion oral de oligonucleotidos.
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010126A (en) 1934-03-19 1935-08-06 Frank L Mclaughlin Measuring and dispensing can
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US5780028A (en) * 1993-09-20 1998-07-14 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
CN1116898C (zh) * 2000-02-21 2003-08-06 湖北楚冠实业股份有限公司 一种口服免疫球蛋白制剂及其制备方法
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
MX2007006086A (es) * 2004-11-25 2007-07-11 Unilever Nv Anticuerpos de cadena pesada y de dominio.
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20080026820A1 (en) * 2006-07-05 2008-01-31 Aruze Gaming America, Inc. Slot machine and playing method thereof
EP2081555A2 (en) 2006-09-12 2009-07-29 Cosmo Technologies Ltd. Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
PT2079445E (pt) * 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20100239682A1 (en) 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (zh) 2009-07-23 2011-02-02 比克国际(天津)有限公司 一种电池组的封装方法及电池组
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
CN105168174B (zh) 2010-03-10 2019-01-08 拉尼医疗有限公司 用于利用可吞咽式药剂递送装置递送到肠道内腔中的治疗剂制剂
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
SI2849723T1 (sl) 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
EP2887960A2 (en) * 2012-08-21 2015-07-01 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
AU2014229282B2 (en) 2013-03-15 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3026012B1 (fr) * 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
EP3277719B1 (en) * 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions

Also Published As

Publication number Publication date
EP3435982A1 (en) 2019-02-06
JP7496906B2 (ja) 2024-06-07
AU2017240190A1 (en) 2018-09-20
KR102376369B1 (ko) 2022-03-18
WO2017171535A3 (en) 2017-12-07
CN117243904A (zh) 2023-12-19
CN109152738A (zh) 2019-01-04
WO2017171535A2 (en) 2017-10-05
IL261792B (en) 2022-06-01
WO2017171535A8 (en) 2017-11-16
US20190008778A1 (en) 2019-01-10
JP2023058591A (ja) 2023-04-25
JP2019514855A (ja) 2019-06-06
CN109152738B (zh) 2023-10-13
KR20190003493A (ko) 2019-01-09
WO2017167997A1 (en) 2017-10-05
AU2023200377A1 (en) 2023-02-23
US10772839B2 (en) 2020-09-15
US20200368167A1 (en) 2020-11-26
IL261792A (en) 2018-10-31
JP7224917B2 (ja) 2023-02-20
CA3053757A1 (en) 2017-10-05
US10980748B2 (en) 2021-04-20
AU2023200377B2 (en) 2025-04-10
CA3019482A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201805072PA (en) Nicotine powder delivery system
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804934PA (en) Novel Compounds
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201909998TA (en) Formulations of human anti-rankl antibodies, and methods of using the same
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201810602YA (en) Method of treating liver fibrosis
SG11201806270XA (en) Gene therapy for treating mucopolysaccharidosis type i
SG11201809594WA (en) Nicotine particles and compositions
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810557XA (en) Aerosol-generating article with an insulated heat source
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201907023UA (en) Method of reducing neutropenia
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof